Pharmaceutical

Morning Rounds: 3D-printed organs, antimicrobial resistance in Ukraine, and other major health stories of the day

Morning Rounds: 3D-printed organs, antimicrobial resist...

Dec 9, 2023

Understand how science, health policy, and medicine shape the world everyday. Si...

CRISPR is about to make history. Here’s the 5-minute rundown of what to expect

CRISPR is about to make history. Here’s the 5-minute ru...

Dec 9, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote

STAT+: Pharmalittle: Biden pharma patent proposal spurs...

Dec 9, 2023

Biden's plan to sidestep certain patents is causing uncertainty over the extent ...

Opinion: STAT+: Health care AI requires a new Hippocratic oath

Opinion: STAT+: Health care AI requires a new Hippocrat...

Dec 9, 2023

Ethical AI guardrails are imperative for health care’s future. A new version of ...

Opinion: Clients bring politics into the therapy room. Here’s what that means for the therapist

Opinion: Clients bring politics into the therapy room. ...

Dec 9, 2023

"Despite a general meaningful aspiration to remain focused on the patient and th...

STAT+: New proposals for scientific misconduct investigations worry some research universities

STAT+: New proposals for scientific misconduct investig...

Dec 9, 2023

Universities and research institutions comment that the U.S. Office of Research ...

STAT+: Sen. Warren pushes for more data on Medicare Advantage coverage hurdles, denials

STAT+: Sen. Warren pushes for more data on Medicare Adv...

Dec 9, 2023

Senators are pushing the Biden administration to collect more data on #MedicareA...

STAT+: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH

STAT+: Historic approval of sickle cell gene therapies ...

Dec 9, 2023

News of the FDA's historic approval of the first gene therapies for sickle cell ...

Pfizer’s multiple myeloma treatment secures conditional approval in EU

Pfizer’s multiple myeloma treatment secures conditional...

Dec 8, 2023

Pfizer’s Elrexfio for treating multiple myeloma has been granted conditional ma...

MSD’s Keytruda and Eisai’s Lenvima fail in Phase III uterine cancer trial

MSD’s Keytruda and Eisai’s Lenvima fail in Phase III ut...

Dec 8, 2023

The combination therapy of MSD’s Keytruda (pembrolizumab) and Eisai’s Lenvima (...

Kymera’s protein degrader starts Phase II trial in atopic dermatitis

Kymera’s protein degrader starts Phase II trial in atop...

Dec 8, 2023

Kymera Therapeutics has dosed the first patient in the Phase II ADVANTA trial e...

Vanda acquires rights to Actelion’s multiple sclerosis drug

Vanda acquires rights to Actelion’s multiple sclerosis ...

Dec 8, 2023

Vanda Pharmaceuticals has acquired rights to Johnson & Johnson (J&J) company Ac...

FDA accepts Alpha Cognition’s NDA for Alzheimer’s disease

FDA accepts Alpha Cognition’s NDA for Alzheimer’s disease

Dec 8, 2023

The US Food and Drug Administration (FDA) has accepted Alpha Cognition’s new dr...

ARTBIO secures $90m to advance ART pipeline

ARTBIO secures $90m to advance ART pipeline

Dec 8, 2023

Clinical-stage radiopharmaceutical company ARTBIO has secured $90m in a Series ...

AbelZeta and AstraZeneca enter CAR-T cell therapy development deal

AbelZeta and AstraZeneca enter CAR-T cell therapy devel...

Dec 8, 2023

AbelZeta Pharma and AstraZeneca have signed an agreement to jointly develop...

Vittoria’s CAR-T therapy secures clinical approval amid FDA scrutiny on sector

Vittoria’s CAR-T therapy secures clinical approval amid...

Dec 8, 2023

Vittoria Biotherapeutics will begin in-human studies of its lead chimeric a...